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Antiplatelet Therapy Changes for Patients With Myocardial Infarction
With Recurrent Ischemic Events: Insights Into Contemporary Practice
From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors:
Longitudinal Assessment of Treatment Patterns and Events After
Acute Coronary Syndrome) Study
Alexander C. Fanaroff, MD; Lisa A. Kaltenbach, MS; Eric D. Peterson, MD, MPH; Mohammed W. Akhter, MD; Mark B. Effron, MD;
Timothy D. Henry, MD; Tracy Y. Wang, MD, MHS, MSc
Background-—Guidelines recommend P2Y12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is
provided on antiplatelet management for patients with recurrent ischemic events during that year. We describe changes in P2Y12
inhibitor type among patients with recurrent ischemic events in the ﬁrst year after MI.
Methods and Results-—The TRANSLATE-ACS (TreatmentWithADPReceptor Inhibitors: Longitudinal Assessment of Treatment Patterns
and Events After AcuteCoronary Syndrome) study enrolled 12 365 patientswithMI treatedwith percutaneous coronary intervention.We
examined whether P2Y12 inhibitor choice changed among patients with recurrent MI, stent thrombosis, and/or unplanned
revascularization during the ﬁrst year after MI, and modeled factors associated with P2Y12 inhibitor intensiﬁcation (changing clopidogrel
to prasugrel or ticagrelor). In the ﬁrst year afterMI, 1414 patients (11%) had a total of 1740 recurrent ischemic events (771 recurrentMIs,
969 unplanned revascularizations, and 165 stent thromboses). Median time to the ﬁrst recurrent ischemic event was 154 days
(25th–75th percentiles, 55–287 days). Of those with recurrent ischemic events, 101 of 1092 (9.3%) occurring in clopidogrel-treated
patients led to P2Y12 inhibitor intensiﬁcation. Recurrent events involving stent thrombosis or MI were the strongest factors associated
with P2Y12 inhibitor intensiﬁcation, yet only 40% of patients with stent thrombosis and 14% of patients with recurrent MI had P2Y12
inhibitor intensiﬁcation. Increasing age and longer time from the index MI were associated with lower likelihood for intensiﬁcation.
Conclusions-—Few patients after MI with a recurrent ischemic event who were taking clopidogrel switched to a more potent P2Y12
inhibitor, even after stent thrombosis events. Speciﬁc guidance is needed for patients who have recurrent ischemic events,
particularly when closely spaced.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01088503. ( J Am Heart Assoc. 2018;7:
e007982. DOI: 10.1161/JAHA.117.007982.)
Key Words: clopidogrel • coronary revascularization • myocardial infarction • secondary prevention • stent thrombosis
G uidelines recommend 1 year of P2Y12 inhibitor therapyin combination with aspirin after acute coronary
syndrome (ACS).1–4 Compared with clopidogrel, the higher-
potency P2Y12 inhibitors, ticagrelor and prasugrel, reduce the
incidence of recurrent cardiovascular events in patients with
ACS undergoing percutaneous coronary intervention (PCI), but
uptake of these agents into clinical practice in the United
States has been tempered by concerns about increased
bleeding risk and higher out-of-pocket patient costs.5–8
Among clopidogrel-treated patients with high on-treatment
platelet activity, prasugrel and ticagrelor have been shown to
effectively inhibit platelet aggregation,9–11 but randomized
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controlled trials switching patients with high on-clopidogrel
platelet reactivity to prasugrel or ticagrelor have failed to
show clinical beneﬁt.12–16 Recurrent ischemic events while
receiving clopidogrel therapy may affect physician decision
making because of perceived clopidogrel “failure,” although
these events may not necessarily reﬂect inadequate platelet
inhibition. In patients with ACS, in-hospital reinfarction while
taking clopidogrel is associated with a higher likelihood of a
switch to prasugrel.17 Postdischarge switching is rare, and
most switches are from prasugrel or ticagrelor to clopidogrel,
driven by cost considerations.18 However, antiplatelet man-
agement of patients with recurrent ischemic events after
hospital discharge has not been previously described, and
consensus guidelines offer no speciﬁc recommendations.
The TRANSLATE-ACS (Treatment With ADP Receptor
Inhibitors: Longitudinal Assessment of Treatment Patterns
and Events After Acute Coronary Syndrome) study enrolled
patients with myocardial infarction (MI) undergoing PCI and
treated with a P2Y12 inhibitor.
15,18,19 Patients were observed
longitudinally after discharge, with independent adjudication
of recurrent MI and revascularization events, core laboratory
adjudication of stent thrombosis, and patient-reported med-
ication adherence. Therefore, the TRANSLATE-ACS study
provided the opportunity to evaluate antiplatelet therapy
changes after recurrent ischemic events.
Methods
Study Population
The design of the TRANSLATE-ACS study has been previously
reported.19 Brieﬂy, the TRANSLATE-ACS study was a
multicenter observational study that examined longitudinal
antiplatelet use and outcomes among 12 365 patients with
MI who were treated with PCI. Patients were enrolled from
April 4, 2010 through October 31, 2012. Eligible patients
were ≥18 years old, diagnosed as having ST-segment–
elevation MI (STEMI) or non-STEMI, treated with PCI and a
P2Y12 inhibitor (clopidogrel, prasugrel, ticlopidine, or tica-
grelor), and able to provide consent for long-term follow-up.
Patients enrolled in another research study that dictated
antiplatelet treatment in the 1 year after MI were excluded.
All patients enrolled in the TRANSLATE-ACS study provided
written informed consent, and the study protocol was
approved by the ethics committee or institutional review
board of each participating site. The Duke University Medical
Center Institutional Review Board (Durham, NC) approved use
of TRANSLATE-ACS study data for this analysis. The data,
analytic methods, and study materials will not be made
available to other researchers for purposes of reproducing the
results or replicating the procedure.
The analysis population for this study began with patients
who were discharged alive after their index PCI event
(Figure 1). The analysis then further focused on the patients
who had a recurrent MI, an unplanned revascularization, or
both during the following 1 year, as deﬁned later.
Data Collection and Deﬁnitions
During each patient’s index MI admission, hospitals collected
baseline demographic and clinical characteristics, processes
of care, discharge medications, and in-hospital outcomes
using data elements and deﬁnitions modiﬁed from the
National Cardiovascular Data Registry CathPCI Registry.
Patients reported current medications and recurrent hospi-
talizations during telephone interviews at 6 weeks, 6 months,
12 months, and 15 months after MI. Patients were queried on
how often they missed taking a dose of their P2Y12 inhibitor;
nonadherence was deﬁned as missing >1 dose per week.
Rehospitalizations were veriﬁed by the collection of medical
bills. Medical records for hospitalizations involving death,
recurrent MI, coronary revascularization (PCI or coronary
artery bypass grafting), or stent thrombosis were collected,
and events were centrally validated using standardized
criteria.19 The diagnosis of MI was validated using a deﬁnition
consistent with the Third Universal Deﬁnition of Myocardial
Infarction.20 Unplanned coronary revascularizations included
both PCI and coronary artery bypass grafting, but excluded
staged revascularizations, deﬁned as those performed within
60 days of the index PCI in the absence of new symptoms.
When stent thrombosis was suspected, coronary angiograms
were independently reviewed by an angiographic core labo-
ratory, and stent thrombosis was validated using Academic
Research Consortium criteria.21 For each event, data were
Clinical Perspective
What Is New?
• Less than 10% of patients after myocardial infarction who
have a recurrent ischemic event while taking clopidogrel are
switched to a more potent P2Y12 inhibitor at the time of the
recurrent event.
• Recurrent events involving stent thrombosis or ST-segment–
elevation myocardial infarction were strongly associated with
switching to a more potent P2Y12 inhibitor, yet only 40% of
patients with stent thrombosis and 37% of patients with
ST-segment–elevation myocardial infarction were switched.
What Are the Clinical Implications?
• Speciﬁc evidence and guidance for the management of
patients with closely spaced ischemic events is lacking, and
a clinical trial in patients after myocardial infarction with
recurrent ischemic events while taking clopidogrel may help
clarify the optimal management strategy for these patients.
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abstracted regarding P2Y12 inhibitor therapy use at the time
of readmission and at discharge.
The primary outcome of our analysis was P2Y12 inhibitor
intensiﬁcation in response to MI or revascularization, which
we deﬁned as a switch from a lower-potency P2Y12 inhibitor
(either clopidogrel or ticlopidine, because some patients
discharged with another agent were switched to ticlopidine
during follow-up) to a higher-potency P2Y12 inhibitor (either
prasugrel or ticagrelor). A switch occurred when the
admission and discharge P2Y12 inhibitors for the hospital-
ization involving the recurrent coronary ischemic event were
different. Patients who were not taking a P2Y12 inhibitor at
the time of their recurrent event were not eligible for
intensiﬁcation, because patients in whom P2Y12 inhibitors
are stopped early are likely to differ substantially from
patients who continue to use P2Y12 inhibitors up to the time
of their event. Increasing clopidogrel dosage to 150 mg/d
was also not considered P2Y12 inhibitor intensiﬁcation
because the TRANSLATE-ACS study did not collect medica-
tion dosages; moreover, the 150-mg/d dose of clopidogrel is
off label.
Statistical Analysis
Patients were grouped ﬁrst according to P2Y12 inhibitor
therapy at the time of their recurrent coronary ischemic event,
and then according to whether they had P2Y12 inhibitor
intensiﬁcation. Descriptive statistics were reported as median
(25th–75th percentile) for continuous variables and frequency
(percentage) for categorical variables. For continuous vari-
ables, differences between groups were compared using the
Wilcoxon rank-sum test. For categorical variables, differences
between groups were assessed using the v2 test when
sample size was sufﬁcient and the Fisher exact test when it
was not sufﬁcient. All analyses were performed at the event
level to enable us to evaluate the effect of multiple recurrent
events on P2Y12 inhibitor intensiﬁcation.
To identify factors associated with P2Y12 inhibitor inten-
siﬁcation, we used logistic regression to create a multivariable
model, assessing candidate variables listed in Data S1. The
logistic regression model used generalized estimating equa-
tions to account for within-patient clustering; discrimination
was assessed by calculating a C-statistic.
Results
P2Y12 Inhibitor Use at Time of Recurrent
Ischemic Events
Among 12 279 patients with MI who were treated with PCI
and discharged alive on a P2Y12 inhibitor, 1414 (11.5%) had
1740 recurrent coronary ischemic events during the ﬁrst year
after MI. These included 771 recurrent MI events (432 treated
with revascularization and 339 treated without revasculariza-
tion) and 969 unplanned coronary revascularizations per-
formed in the absence of a recurrent MI. Of MI events, 165
(21.4%) involved stent thrombosis. Median time to the ﬁrst
recurrent ischemic event was 154 days (25th–75th per-
centile, 54–287 days). At the time of the recurrent ischemic
event, 1087 patients (62.5%) were taking clopidogrel, 5
patients (0.3%) were taking ticlopidine, 381 patients (21.9%)
were taking prasugrel, and 55 patients (3.2%) were taking
ticagrelor. Only 5% of recurrent ischemic events occurred in
patients who were prescribed P2Y12 inhibitors at the time of
the event but reported nonadherence to therapy. Although all
recurrent ischemic events occurred within 1 year of the index
MI, 212 patients (12.2%) were no longer taking a P2Y12
inhibitor at the time of the recurrent event.
Figure 1. Study ﬂow diagram. MI indicates myocardial infarction; and TRANSLATE-ACS, Treatment With
ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary
Syndrome.
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Table 1. Baseline Patient Characteristics by P2Y12 Inhibitor at the Time of the Recurrent Ischemic Event
Characteristics
Overall
(N=1740)
Clopidogrel/
Ticlopidine (n=1092)
None
(n=212)
Prasugrel/
Ticagrelor (n=436) P Value
Demographics
Age, y 61 (52–69) 61 (53–70) 61 (51–69) 57 (50–65) <0.001
Male sex 1168 (67.1) 736 (67.4) 133 (62.7) 299 (68.6) 0.32
White race 1472 (84.6) 928 (85.0) 165 (77.8) 379 (86.9) 0.007
Health insurance
Private 1000 (57.5) 630 (57.7) 93 (43.9) 277 (63.5) <0.001
Medicare 731 (42.0) 501 (45.9) 98 (46.2) 132 (30.3) <0.001
Medicaid 184 (10.6) 116 (10.6) 29 (13.7) 39 (8.9) 0.21
None 234 (13.5) 133 (12.2) 43 (20.3) 58 (13.3) 0.007
Financial hardship of
paying for medications
429 (26.8) 270 (26.6) 62 (33.9) 97 (24.2) 0.05
Married 1027 (59.0) 649 (59.4) 92 (43.4) 286 (65.6) <0.001
High school graduate
or beyond
1449 (83.3) 903 (82.7) 166 (78.3) 380 (87.2) 0.01
Employed 689 (39.6) 395 (36.2) 61 (28.8) 233 (53.4) <0.001
Medical history at the time of index event
Prior CABG 348 (20.0) 250 (22.9) 30 (14.2) 68 (15.6) <0.001
Prior stroke or TIA 132 (7.6) 94 (8.6) 28 (13.2) 10 (2.3) <0.001
PAD 233 (13.4) 164 (15.0) 35 (16.5) 34 (7.8) <0.001
Prior heart failure 230 (13.2) 157 (14.4) 33 (15.6) 40 (9.2) 0.02
Atrial fibrillation/flutter 124 (7.1) 84 (7.7) 18 (8.5) 22 (5.1) 0.14
Diabetes mellitus 725 (41.7) 452 (41.4) 90 (42.5) 183 (42.0) 0.94
Chronic lung disease 249 (14.3) 173 (15.8) 32 (15.1) 44 (10.1) 0.01
Features of index admission
STEMI 791 (45.5) 448 (41.0) 112 (52.8) 231 (53.0) <0.001
Multivessel disease 1151 (66.2) 736 (67.4) 132 (62.3) 283 (64.9) 0.24
Platelet function
testing performed
246 (14.1) 143 (13.1) 28 (13.2) 75 (17.2) 0.11
LVEF ≤40% 387 (25.2) 242 (25.4) 47 (25.4) 98 (24.8) 0.97
BMI, kg/m2 29 (26–34) 29 (26–34) 29 (26–33) 30 (27–34) 0.13
GFR, mL/min 73 (57–91) 71 (55–91) 74 (51–92) 77 (60–93) 0.02
Platelet function
testing performed
246 (14.1) 28 (13.2) 143 (13.1) 75 (17.2) 0.11
Features of index PCI
Location 0.05
Left main 22 (1.3) 10 (0.9) 4 (1.9) 8 (1.8)
LAD 578 (33.2) 360 (33.0) 74 (34.9) 144 (33.0)
LCX 429 (24.7) 295 (27.1) 47 (22.2) 87 (20.0)
RCA 695 (40.0) 419 (38.4) 84 (39.6) 192 (44.0)
Lesion involved stent thrombosis 80 (4.6) 35 (3.2) 15 (7.1) 30 (6.9) 0.01
Lesion involved vein graft 174 (10.0) 137 (12.6) 9 (4.3) 28 (6.4) <0.001
Drug-eluting stent implanted 1097 (63.1) 676 (61.9) 104 (49.1) 317 (72.7) <0.001
Continued
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Compared with patients no longer taking a P2Y12 inhibitor,
patients taking clopidogrel had a shorter time from their index
event to the recurrent event (148 versus 193 days; P=0.003)
(Table 1). Patients taking clopidogrel were less likely to have a
recurrent MI or stent thrombosis and more likely to have an
unplanned revascularization alone compared with patients no
longer taking a P2Y12 inhibitor. In patients with recurrent
ischemic events after P2Y12 inhibitor discontinuation, these
events occurred at a median of 92 days (25th–75th per-
centiles, 37–191 days) after P2Y12 inhibitor discontinuation.
Compared with patients taking a higher-potency P2Y12
inhibitor at the time of the recurrent ischemic event, patients
taking clopidogrel were older and more often had prior
coronary artery bypass grafting, prior stroke/transient
ischemic attack, and peripheral artery disease. Among
patients taking clopidogrel at the time of the recurrent event,
51 (5%) were discharged on a higher-potency P2Y12 inhibitor
and then switched to clopidogrel; the recurrent ischemic
event occurred at a median of 218 days (25th–75th per-
centile, 131–301 days) after P2Y12 inhibitor switching. Time
from index to recurrent event and type of recurrent event
were similar between patients still taking lower- versus
higher-potency P2Y12 inhibitors. Stent thrombosis was
observed in 21.8% of patients no longer taking a P2Y12
inhibitor, 8.3% of patients taking clopidogrel or ticlopidine,
and 6.7% of patients taking a higher-potency P2Y12 inhibitor
(P<0.0001).
Changes in P2Y12 Inhibitor Therapy After
Recurrent Ischemic Events
Overall, 353 patients (20.3%) changed P2Y12 inhibitors at the
time of their recurrent ischemic event (Figure 2). Among
patients with MI, 178 (23.2%) changed; 116 patients (11.8%)
with revascularization only changed, and 85 patients (51.5%)
with stent thrombosis changed.
Of the 212 patients no longer taking a P2Y12 inhibitor at the
time of the recurrent ischemic events, 117 (55.2%) were
reinitiated on a P2Y12 inhibitor (74 [34.9%] started taking
clopidogrel, and 42 [19.8%] started taking a higher-potency
P2Y12 inhibitor). Among the 436 patients taking prasugrel or
ticagrelor at the time of the recurrent ischemic event, 13 (3.0%)
Table 1. Continued
Characteristics
Overall
(N=1740)
Clopidogrel/
Ticlopidine (n=1092)
None
(n=212)
Prasugrel/
Ticagrelor (n=436) P Value
Discharge medications after index MI
P2Y12 inhibitor
Clopidogrel 1254 (72.1) 1026 (94.0) 153 (72.5) 75 (17.2) <0.001
Prasugrel 414 (23.8) 51 (4.7) 48 (22.8) 315 (72.3) <0.001
Ticlopidine 8 (0.5) 8 (0.7) 0 (0) 0 (0) 0.09
Ticagrelor 55 (3.2) 4 (0.4) 5 (2.4) 46 (10.6) <0.001
None 8 (0.5) 3 (0.3) 5 (2.4) 0 (0) <0.001
Anticoagulant 114 (6.6) 72 (6.6) 25 (11.8) 17 (3.9) <0.001
Bleeding between index and follow-up event
Moderate-severe >30 d before 34 (2.0) 9 (0.8) 17 (8.0) 8 (1.8) <0.001
Moderate-severe ≤30 d before 51 (2.9) 34 (3.1) 10 (4.7) 7 (1.6) 0.07
Mild >30 d before 39 (2.2) 22 (2.0) 9 (4.3) 8 (1.8) 0.11
Mild ≤30 d before 44 (2.5) 30 (2.8) 8 (3.8) 6 (1.4) 0.14
Features of recurrent ischemic event
Time to event, d 154 (55–287) 148 (52–279) 193 (74–323) 157 (52–288) 0.03
Type of event <0.001
MI with revascularization 432 (24.8) 253 (23.2) 90 (42.5) 89 (20.4)
MI without revascularization 339 (19.5) 201 (18.4) 68 (32.1) 70 (16.1)
Revascularization without MI 969 (55.7) 638 (58.4) 54 (25.5) 277 (63.5)
Stent thrombosis adjudicated 165 (9.5) 91 (8.3) 45 (21.2) 29 (6.7) <0.001
Categorical variables are presented as frequency (percentage); continuous variables are presented as median (25th–75th percentile). Generation 1 P2Y12 inhibitors are deﬁned as
clopidogrel or ticlopidine; generation 2 P2Y12 inhibitors are deﬁned as prasugrel or ticagrelor. BMI indicates body mass index; CABG, coronary artery bypass grafting; GFR, glomerular
ﬁltration rate; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery
disease; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment–elevation MI; and TIA, transient ischemic attack.
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switched to the other high-potency P2Y12 inhibitor (10 after
recurrent MI and 3 after unplanned revascularization without
MI) and 34 (7.8%) switched to clopidogrel (18 after recurrent MI
and 16 after unplanned revascularization without MI).
Of the 1092 patients taking clopidogrel or ticlopidine at the
time of their event, 101 (9.3%) switched to a higher-potency
P2Y12 inhibitor, deﬁned as P2Y12 inhibitor intensiﬁcation.
Patients with MI were more likely to have P2Y12 inhibitor
intensiﬁcation than those with revascularization only. Of 450
patients with a recurrent MI while taking clopidogrel, 65
(14.4%) were switched to prasugrel or ticagrelor; 36 of 637
patients (5.7%) were switched to a higher-potency P2Y12
inhibitor after an unplanned revascularization event without
MI (P<0.001). Among 175 patients who were taking clopido-
grel at the time of a second or higher recurrent ischemic
event, 20 (11.4%) had P2Y12 inhibitor intensiﬁcation.
P2Y12 Inhibitor Intensiﬁcation
Patients with P2Y12 inhibitor intensiﬁcation (n=101) at the
time of their recurrent coronary ischemic event were younger
than those without intensiﬁcation (n=991) (57 versus
62 years; P<0.001). They less often had prior coronary artery
bypass grafting, peripheral artery disease, multivessel coro-
nary artery disease, and atrial ﬁbrillation/ﬂutter. Bleeding
events between index and recurrent events were rare and did
not differ signiﬁcantly between those with and without
intensiﬁcation (Table 2). Patients with P2Y12 inhibitor
intensiﬁcation had their recurrent events sooner after the
index event than patients without intensiﬁcation (83 versus
154 days; P<0.001), more often had MIs rather than revas-
cularization alone (64.3 versus 39.3%; P<0.001), and more
often had STEMI (33.7% versus 5.7%; P<0.001) and stent
thrombosis (35.6% versus 5.6%; P<0.001).
On multivariable modeling, 4 patient features were signif-
icantly associated with intensiﬁcation of antiplatelet therapy
(Figure 3). Stent thrombosis was the strongest feature (odds
ratio, 4.45; 95% conﬁdence interval, 2.37–8.34), and presen-
tation with MI rather than revascularization alone also had a
positive association with P2Y12 inhibitor intensiﬁcation.
Younger age and shorter duration from index MI event were
also associated with a higher incidence of intensiﬁcation
(odds ratio, 1.12 per 1-month decrease in duration from index
to recurrent event [95% conﬁdence interval, 1.05–1.19]; odds
ratio, 1.39 per 10-year decrease in age [95% conﬁdence
interval, 1.14–1.69]). Financial hardship of paying for medi-
cations, diabetes mellitus, and moderate/severe bleeding
between the index MI and the time of the recurrent ischemic
event each had no signiﬁcant association with the likelihood
of intensifying P2Y12 inhibitor therapy. The C-statistic for the
multivariable model was 0.77.
Although stent thrombosis was the strongest factor
associated with P2Y12 inhibitor intensiﬁcation, only 36 of 91
patients (40%) with stent thrombosis while taking clopidogrel
were switched to either prasugrel or ticagrelor. Of 90 patients
with STEMI, 34 (37%) had P2Y12 inhibitor intensiﬁcation.
Figure 2. Percentage of patients with escalation and deescalation of antiplatelet therapy. Clop indicates
clopidogrel; MI, myocardial infarction; Pras, prasugrel; and Ticag, ticagrelor.
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Discussion
Within 1 year after MI treated with PCI, 11% of patients
experienced a recurrent ischemic event; most occurred while
the patient was still taking guideline-recommended P2Y12
inhibitor therapy. Time from index to recurrent event and type
of recurrent event were similar between patients taking lower-
versus higher-potency P2Y12 inhibitors. Among patients
taking a lower-potency P2Y12 inhibitor, only 9% intensiﬁed
Table 2. Baseline Patient Characteristics by Intensiﬁcation
Status Among Patients Taking Clopidogrel or Ticlopidine at
the Time of Follow-Up Event
Variable
Intensiﬁcation
(n=101)
No
Intensiﬁcation
(n=991) P Value
Demographics
Age, y 57 (49–68) 62 (54–70) <0.001
Male sex 63 (62.4) 673 (67.9) 0.26
White race 82 (81.2) 846 (85.4) 0.32
Health insurance
Private 54 (53.5) 576 (58.1) 0.36
Medicare 38 (37.6) 463 (46.7) 0.08
Medicaid 12 (11.9) 104 (10.5) 0.67
None 12 (11.9) 121 (12.2) 0.91
Financial hardship
of paying for
medications
32 (33.7) 238 (25.8) 0.10
Married 57 (56.4) 592 (59.7) 0.56
High school graduate
or beyond
86 (85.2) 817 (82.4) 0.39
Employed 48 (47.5) 347 (35.0) 0.01
Weight, kg 84 (74–102) 86 (75–102) 0.31
BMI, kg/m2 29 (26–33) 29 (26–34) 0.75
GFR, mL/min 79 (60–95) 71 (55–90) 0.07
Medical history at the time of index event
Prior CABG 10 (9.9) 240 (24.2) 0.001
Prior stroke or TIA 11 (10.9) 83 (8.4) 0.39
PAD 8 (7.9) 156 (15.8) 0.04
Prior heart failure 10 (9.9) 147 (14.8) 0.19
Atrial fibrillation/flutter 2 (2.0) 82 (8.3) 0.03
Diabetes mellitus 41 (40.6) 411 (41.5) 0.91
Smoker 43 (42.6) 330 (33.3) 0.06
Chronic lung disease 13 (12.9) 160 (16.2) 0.40
Features of index admission
Multivessel disease 55 (54.5) 681 (68.7) 0.008
LVEF ≤40% 23 (26.7) 219 (25.3) 0.69
Culprit lesion location 0.12
Left main 0 (0) 10 (1.0)
LAD 43 (42.6) 317 (32.0)
LCX 23 (22.8) 272 (27.5)
RCA 33 (32.7) 386 (39.0)
Drug-eluting stent
implanted
55 (54.5) 621 (62.7) 0.12
Platelet function
testing performed
11 (10.9) 132 (13.3) 0.49
Continued
Table 2. Continued
Variable
Intensiﬁcation
(n=101)
No
Intensiﬁcation
(n=991) P Value
Discharge medications
P2Y12 inhibitor
Clopidogrel 88 (87.1) 938 (94.7) 0.003
Prasugrel 10 (9.9) 41 (4.1) 0.009
Ticlopidine 0 (0) 8 (0.8) 0.37
Ticagrelor 1 (1.0) 3 (0.3) 0.28
None 2 (2.0) 1 (0.1) <0.001
Anticoagulant 4 (4.0) 68 (6.9) 0.26
Bleeding between index and follow-up event
Moderate-severe
>30 d before
1 (1.0) 8 (0.8) 0.85
Moderate-severe
≤30 d before
1 (1.0) 33 (3.3) 0.20
Mild >30 d before 0 (0) 22 (2.2) 0.13
Mild ≤30 d before 0 (0) 30 (3.0) 0.08
Features of follow-up event
Time to event, d 83 (9–178) 154 (57–285) <0.001
Type of event <0.001
MI with revascularization 52 (51.5) 201 (20.3)
MI without
revascularization
13 (12.9) 188 (19.0)
Revascularization
without MI
36 (35.7) 602 (60.8)
MI type: STEMI 34 (33.6) 56 (5.6) <0.001
Stent thrombosis 36 (35.6) 55 (5.6) <0.001
Nonadherent to
P2Y12 inhibitor
8 (7.9) 54 (5.5) 0.31
Culprit vessel previously
stented lesion
55 (62.5) 282 (35.1) <0.001
Categorical variables are presented as frequency (percentage); continuous variables are
presented as median (25th–75th percentile). Intensiﬁcation deﬁned as switch from
clopidogrel to prasugrel or ticagrelor within 7 days after the recurrent event. BMI
indicates body mass index; CABG, coronary artery bypass grafting; GFR, glomerular
ﬁltration rate; LAD, left anterior descending coronary artery; LCX, left circumﬂex
coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD,
peripheral artery disease; RCA, right coronary artery; STEMI, ST-segment–elevation MI;
and TIA, transient ischemic attack.
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to prasugrel or ticagrelor after their recurrent ischemic event.
Switching between higher-potency P2Y12 inhibitors (ticagrelor
to prasugrel, or vice versa) was infrequent (3.0%). Recurrent
MI (compared with revascularization without MI) and
stent thrombosis were strongly associated with P2Y12
inhibitor intensiﬁcation; yet, only 40% of patients with stent
thrombosis and 14% of patients with recurrent MI had P2Y12
inhibitor intensiﬁcation. Increasing age and longer time from
the index MI were also associated with lower likelihood for
intensiﬁcation.
No prior study has evaluated the incidence and predictors
of intensifying P2Y12 inhibitor therapy in response to recur-
rent coronary ischemic events in patients with recent MI
treated with PCI. A previous analysis examined switching from
clopidogrel to a higher-potency P2Y12 inhibitor during the
index MI hospitalization; younger age, private health insur-
ance, and presentation with STEMI were associated with
intensiﬁcation of P2Y12 inhibitor therapy, whereas prior
history of atrial ﬁbrillation, stroke, peripheral artery disease,
or heart failure were associated with clopidogrel continuation.17
Patients switched to a higher-potency P2Y12 inhibitor were
more likely to have had a recurrent MI during their index
hospitalization than patients continued on clopidogrel. In
another TRANSLATE-ACS analysis, 7.6% of patients switched
P2Y12 inhibitors in the year after their ACS event; two thirds of
these switches were from prasugrel or ticagrelor to clopido-
grel, and many switches cited cost as the primary motivating
factor.18 Of patients switching from clopidogrel to a higher-
potency P2Y12 inhibitor, 18.5% had an ischemic event in the
7 days before the switch, including 5.6% with a stent
thrombosis.
Younger age remained associated with P2Y12 inhibitor
intensiﬁcation after a postdischarge recurrent ischemic event.
The negative association between increasing age and P2Y12
inhibitor intensiﬁcation may reﬂect clinician wariness of
bleeding with higher-potency P2Y12 inhibitor use in older
patients, as seen in the pivotal clinical trials evaluating these
agents.7 Bleeding risk is likely further exacerbated by
extending antiplatelet treatment duration as a result of the
recurrent ischemic event.22,23 On-treatment recurrent MI
events were strongly associated with P2Y12 inhibitor intensi-
ﬁcation both during the index MI hospitalization and postdis-
charge, presumably reﬂecting clinicians’ acceptance of the
beneﬁt of higher-potency platelet inhibition in patients with
recurrent MI.24 Surprisingly, shorter duration of time between
the index and recurrent ischemic events was a predictor of
P2Y12 inhibitor intensiﬁcation. Longer duration of antiplatelet
treatment from index to the later recurrent event may indicate
patients better able to persist with antiplatelet therapy
without bleeding, which we had expected would increase
the likelihood of P2Y12 inhibitor intensiﬁcation. However,
clinicians may view a period of clinical stability after the index
MI as a positive prognostic indicator. When the patient had a
recurrent event soon after the prior event while taking a
lower-potency P2Y12 inhibitor, it may be interpreted as a sign
of “treatment failure.”
Although intensiﬁcation of antiplatelet therapy appears to
be more common with STEMI and stent thrombosis, it
Figure 3. Multivariable model of antiplatelet intensiﬁcation (deﬁned as switching from clopidogrel to
prasugrel or ticagrelor) for patients taking clopidogrel at the time of a recurrent vascular event. The asterisk
indicates discharged on prasugrel after index myocardial infarction (MI), and switched to clopidogrel before
follow-up event. CI indicates conﬁdence interval.
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remains infrequent. Less than 10% of patients with a recurrent
ischemic event while taking clopidogrel switched to a higher-
potency P2Y12 inhibitor. Guideline updates in 2014 provided a
class IIa recommendation for higher-potency P2Y12 inhibitors
in preference to clopidogrel,1,25 but there is no direct
evidence speciﬁc to patients with recurrent ischemic events
while taking P2Y12 inhibitor therapy. In routine clinical
practice, physician decisions about antiplatelet therapy choice
may be based on several factors unique to the individual
patient, including predicted risk of recurrent events, predicted
safety, and cost of treatment. Although patients with diabetes
mellitus have been shown to beneﬁt from higher-potency
P2Y12 inhibitor therapy,
26,27 diabetes mellitus was not a
signiﬁcant factor associated with P2Y12 inhibitor intensiﬁca-
tion. Bleeding before the recurrent ischemic event was rare,
and its rarity likely explains its lack of statistically signiﬁcant
association with P2Y12 inhibitor intensiﬁcation. The point
estimate for the association between recent moderate/
severe bleeding and P2Y12 inhibitor intensiﬁcation was 0.36,
trending toward lower likelihood of P2Y12 inhibitor intensiﬁ-
cation. There was a trend toward P2Y12 inhibitor intensiﬁca-
tion among patients initially discharged on a higher-potency
P2Y12 inhibitor after their index event who switched to
clopidogrel after discharge and then developed a recurrent
ischemic event. It is perhaps reassuring that patient ﬁnancial
hardship paying for medications did not affect physician
decision making in the setting of a recurrent ischemic event.
Although high on-clopidogrel platelet reactivity is prevalent
and associated with a higher risk of recurrent ischemic
events,28–30 and several studies have shown that switching
between P2Y12 inhibitors is safe and effectively reduces
platelet reactivity in patients with high on-clopidogrel platelet
reactivity,31 no randomized controlled trial has demonstrated
that intensifying P2Y12 inhibition reduces clinical end points in
patients with high on-clopidogrel platelet reactivity.12–16
Platelet function testing is infrequently performed in current
practice,15 and recurrent ischemic events while taking
clopidogrel may not necessarily reﬂect inadequate platelet
inhibition. The low rates of P2Y12 inhibitor intensiﬁcation
observed, 37% of patients with STEMI and 40% of patients
with stent thrombosis, underscore clinical inertia in the
absence of data and guideline recommendations. A clinical
trial that tests P2Y12 inhibitor intensiﬁcation for patients with
recurrent ischemic events taking clopidogrel (10% of
patients with ACS) may help clarify optimal management for
this patient population and provide evidence to guide
physician decision making.
Limitations
This is a secondary analysis of observational data and is
subject to unmeasured confounding and selection bias.
Because of the limited number of patients with P2Y12 inhibitor
intensiﬁcation, the number of variables tested in the multi-
variable model was limited to prevent overﬁtting. Variables
were chosen on the basis of clinical reasoning, but other
variables not included in the model may be important to
physician decision making. Furthermore, the results of
platelet function testing may play a role in decisions about
P2Y12 inhibitor intensiﬁcation; however, the TRANSLATE-ACS
study did not collect data on platelet function testing at the
time of recurrent ischemic events. There was no association
between platelet function testing at the time of the index
admission and P2Y12 inhibitor intensiﬁcation in response to
recurrent events. Routine platelet function testing is not
recommended by consensus guidelines and is rare in clinical
practice, and physicians infrequently change antiplatelet
therapy in response to its results.1,3,32,33 Medication nonad-
herence may play a role in physician decision making and is
often underestimated with patient self-reporting,34 but it was
reported in only 5% of patients with recurrent ischemic events
in our study. Approximately 12% of patients were not taking a
P2Y12 inhibitor at the time of their recurrent event, even
though guidelines recommend 1 year of P2Y12 inhibitor
therapy after MI. Adherence to guidelines is not perfect in
clinical practice, and patients and physicians may have opted
to stop P2Y12 inhibitor therapy early for several reasons.
Persistence with P2Y12 inhibitor therapy in our cohort is in
line with other published reports.35–37 TRANSLATE-ACS study
event adjudication did not differentiate between type I and
type II recurrent MIs, which may also affect clinician decision
making with respect to prescription of antiplatelet therapy.
Nearly 45% of recurrent MIs in the TRANSLATE-ACS study
were treated without revascularization, and physicians may be
more likely to intensify P2Y12 inhibitor therapy in patients with
invasively managed MI. Our results may, therefore, underes-
timate the rate of P2Y12 inhibitor intensiﬁcation in response
to a type I MI in clinical practice, although distinguishing
between type I and II MIs is difﬁcult in both the clinical and
research setting. In addition, ticagrelor was released in the
United States during the conduct of the TRANSLATE-ACS
study, and was used infrequently by patients enrolled in the
study; only 2.1% of patients in the TRANSLATE-ACS study
were treated with ticagrelor at the time of their index event.
Practice changes since the TRANSLATE-ACS study period
show a small, but signiﬁcant, increase in uptake of higher-
potency P2Y12 inhibitors in the United States, and these data
may not fully reﬂect current practices; however, >50% of
patients with ACS are still treated with clopidogrel in many
contemporary US registries.8,38,39 Last, because patients in
the TRANSLATE-ACS study were only observed for 15 months
after the index MI event, we are unable to report outcomes for
patients with P2Y12 inhibitor intensiﬁcation in response to
recurrent events compared with those without intensiﬁcation.
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Conclusion
Within 1 year after MI treated with PCI, 11% of patients
experienced a recurrent ischemic event; most occurred while
the patient was still taking guideline-recommended P2Y12
inhibitor therapy. Among patients taking a lower-potency
P2Y12 inhibitor, few intensiﬁed to a higher-potency P2Y12
inhibitor at the time of a recurrent ischemic event, even
among those with STEMI or stent thrombosis. Physicians are
more likely to intensify P2Y12 inhibitor therapy in response to
a recurrent MI or stent thrombosis and in patients of younger
age or those who develop the recurrent ischemic event
sooner after the index event. Whether intensiﬁcation reduces
further cardiovascular events in this high-risk population
warrants further investigation to generate speciﬁc guideline
recommendations.
Sources of Funding
The TRANSLATE-ACS (Treatment With ADP Receptor Inhibi-
tors: Longitudinal Assessment of Treatment Patterns and
Events After Acute Coronary Syndrome) study is sponsored by
Daiichi Sankyo, Inc, and Lilly. The Duke Clinical Research
Institute is the coordinating center for this study, which
represents a collaborative effort with the American College of
Cardiology.
Disclosures
Fanaroff reports grants from the National Institutes of Health
(5T32HL069749-13) and the American Heart Association
(17FTF33661087); and research funding from Gilead
Sciences. Peterson reports research funding from the Amer-
ican College of Cardiology, American Heart Association, Eli
Lilly & Company, Janssen Pharmaceuticals, and Society of
Thoracic Surgeons; and consulting for Merck & Co, Boehringer
Ingelheim, Genentech, Janssen Pharmaceuticals, and Sanoﬁ-
Aventis. Effron reports being an employee of Eli Lilly and
Company at the time of the study and a shareholder of Eli Lilly
and Company (signiﬁcant). Wang reports research grants to
the Duke Clinical Research Institute from AstraZeneca,
Boston Scientiﬁc, Daiichi Sankyo, Eli Lilly, Gilead Sciences,
Glaxo Smith Kline, and Regeneron Pharmaceuticals; honorar-
ium for educational activities from AstraZeneca; and consult-
ing for Eli Lilly and Astra Zeneca. The remaining authors have
no disclosures to report.
References
1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR,
Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D,
Peterson ED, Sabatine MS, Smalling RS, Zieman SJ. 2014 AHA/ACC guideline
for the management of patients with non-ST-elevation acute coronary
syndromes. Circulation. 2014;130:e344–e426.
2. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA,
Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM,
Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-
Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction. Circula-
tion. 2012;127:e362–e425.
3. Rofﬁ M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
Borger MA, Brotons C, Chew DP. 2015 ESC Guidelines for the management of
acute coronary syndromes in patients presenting without persistent ST-
segment elevation. Eur Heart J. 2016;37:267–315.
4. Ibanez B, James SK, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio AL, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
Lenzen MJ, Prescott E, Rofﬁ M, Valgimigli M, Varenhorst C, Vranckx P,
Widimsky P. 2017 ESC Guidelines for the management of acute myocardial
infarction in patients presenting with ST-segment elevation. Eur Heart J.
2017;39:119–177.
5. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J,
Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK.
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary
syndrome with or without revascularization: results from the PLATO trial. Eur
Heart J. 2014;35:2083–2093.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J,
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G,
Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med. 2007;357:2001–2015.
8. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM.
Contemporary trends in oral antiplatelet agent use in patients treated with
percutaneous coronary intervention for acute coronary syndrome. J Manag
Care Spec Pharm. 2017;23:57–63.
9. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L,
Storey RF, Nielsen T, Eikelboom JW. Response to ticagrelor in clopidogrel
nonresponders and responders and effect of switching therapies. Circulation.
2010;121:1188–1199.
10. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G,
Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-
clopidogrel platelet reactivity post-stenting more effectively than high-dose
(150-mg) clopidogrel. JACC Cardiovasc Interv. 2011;4:403–410.
11. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti T-E, Panagiotou A,
Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet
reactivity in chronic coronary artery disease patients more effectively than
high dose (150 mg) clopidogrel. Am Heart J. 2011;162:733–739.
12. Collet J-P, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff
P, Carrie D, Boueri Z. Bedside monitoring to adjust antiplatelet therapy for
coronary stenting. N Engl J Med. 2012;367:2100–2109.
13. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G,
Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel
in patients with high platelet reactivity on clopidogrel after elective percuta-
neous coronary intervention with implantation of drug-eluting stents: results of
the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective
Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel)
study. J Am Coll Cardiol. 2012;59:2159–2164.
14. Price MJ, Berger PB, Teirstein PS, Tanguay J-F, Angiolillo DJ, Spriggs D, Puri S,
Robbins M, Garratt KN, Bertrand OF. Standard-vs high-dose clopidogrel based
on platelet function testing after percutaneous coronary intervention: the
GRAVITAS randomized trial. J Am Med Assoc. 2011;305:1097–1105.
15. Wang TY, Henry TD, Effron MB, Honeycutt E, Hess CN, Zettler ME, Cohen DJ,
Baker BA, Berger PB, Anstrom KJ. Cluster-randomized clinical trial examining
the impact of platelet function testing on practice the treatment with
adenosine diphosphate receptor inhibitors: longitudinal assessment of treat-
ment patterns and events after acute coronary syndrome prospective open
label antiplatelet therapy study. Circ Cardiovasc Interv. 2015;8:e001712.
16. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C,
Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R. Platelet function
monitoring to adjust antiplatelet therapy in elderly patients stented for an
acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint,
randomised controlled superiority trial. Lancet. 2016;388:2015–2022.
17. Bagai A, Wang Y, Wang TY, Curtis JP, GurmHS, Shah B, Cheema AN, Peterson ED,
Saucedo JF, Granger CB. In-hospital switching between clopidogrel and prasugrel
among patients with acute myocardial infarction treated with percutaneous
coronary intervention insights into contemporary practice from the national
cardiovascular data registry. Circ Cardiovasc Interv. 2014;7:585–593.
18. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker
BA, Messenger JC, Cohen DJ, Wang TY. Switching of adenosine diphosphate
DOI: 10.1161/JAHA.117.007982 Journal of the American Heart Association 10
Antiplatelet Switching After Recurrent Events Fanaroff et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
receptor inhibitor after hospital discharge among myocardial infarction
patients: insights from the Treatment with Adenosine Diphosphate Receptor
Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J.
2017;183:62–68.
19. Chin CT, Wang TY, Anstrom KJ, Zhu B, Maa JF, Messenger JC, Ryan KA,
Davidson-Ray L, Zettler M, Effron MB, Mark DB, Peterson ED. Treatment with
adenosine diphosphate receptor inhibitors-longitudinal assessment of treat-
ment patterns and events after acute coronary syndrome (TRANSLATE-ACS)
study design: expanding the paradigm of longitudinal observational research.
Am Heart J. 2011;162:844–851.
20. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA,
Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax
JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm
CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman
EM, Antman EM, Wallentin LC, Armstrong PW, SimoonsML, Januzzi JL, Nieminen
MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD,
Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D,
Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal
deﬁnition of myocardial infarction. Circulation. 2012;126:2020–2035.
21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, Steg PG,
Morel MA, Mauri L, Vranckx P. Clinical end points in coronary stent trials a
case for standardized deﬁnitions. Circulation. 2007;115:2344–2351.
22. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,
Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P,
Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott
SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients
with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
23. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW,
Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK,
Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet
therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
24. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D,
Maurer G, Morais J, Nicolau JC. Reduction in ﬁrst and recurrent cardiovascular
events with ticagrelor compared with clopidogrel in the PLATO Study.
Circulation. 2013;127:673–680.
25. Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G,
Hamm C, Head SJ, J€uni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U,
Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa UVA M, Stefanini GG,
Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS
Guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–2619.
26. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J,
Nicolau JC, Spinar J, Storey RF. Ticagrelor vs. clopidogrel in patients with acute
coronary syndromes and diabetes: a substudy from the PLATelet inhibition and
patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006–3016.
27. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW,
Goodman SG, Corbalan R, Purdy DA, Murphy SA. Greater clinical beneﬁt of
more intensive oral antiplatelet therapy with prasugrel in patients with
diabetes mellitus in the trial to assess improvement in therapeutic outcomes
by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial
Infarction 38. Circulation. 2008;118:1626–1636.
28. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR,
Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450
polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–
362.
29. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L,
Sibbing D, Collet J-P. Expert position paper on the role of platelet function
testing in patients undergoing percutaneous coronary intervention. Eur Heart J.
2014;35:209–215.
30. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC,
Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane
AJ, Brodie BR, Mehran R, Stuckey TD. Platelet reactivity and clinical outcomes
after coronary artery implantation of drug-eluting stents (ADAPT-DES): a
prospective multicentre registry study. Lancet. 2013;382:614–623.
31. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in
patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11.
32. Wang TY, Henry TD, McCoy LA, Berger PB, Cohen DJ, Effron MB, Zettler M,
Baker BA, Messenger JC, Peterson ED. Contemporary use of platelet function
and pharmacogenomic testing among patients with acute myocardial infarc-
tion undergoing percutaneous coronary intervention in the United States. Am
Heart J. 2015;170:706–714.
33. Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, Henry TD,
Cohen DJ, Schulte PJ, Anstrom KJ. Association of measured platelet reactivity
with changes in P2Y 12 receptor inhibitor therapy and outcomes after
myocardial infarction: insights into routine clinical practice from the TReat-
ment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment
Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study.
Am Heart J. 2017;187:19–28.
34. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of
self-report with other measures of medication adherence: a summary of the
literature. Med Care. 2004;42:649–652.
35. Green A, Pottegard A, Broe A, Diness TG, Emneus M, Hasvold P, Gislason GH.
Initiation and persistence with dual antiplatelet therapy after acute myocardial
infarction: a Danish nationwide population-based cohort study. BMJ Open.
2016;6:e010880.
36. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini
AS, Stuckey T, Cohen DJ. Cessation of dual antiplatelet treatment and cardiac
events after percutaneous coronary intervention (PARIS): 2 year results from a
prospective observational study. Lancet. 2013;382:1714–1722.
37. Fosbøl EL, Ju C, Anstrom KJ, Zettler ME, Messenger JC, Waksman R, Effron
MB, Baker BA, Cohen DJ, Peterson ED. Early cessation of adenosine
diphosphate receptor inhibitors among acute myocardial infarction patients
treated with percutaneous coronary intervention. Circ Cardiovasc Interv.
2016;9:e003602.
38. Basra SS, Wang TY, Simon DN, Chiswell K, Virani SS, Alam M, Nambi V,
Denktas AE, Deswal A, Ballantyne CM. Contemporary patterns of use of
antiplatelet agents in patients with acute myocardial infarction: insight from
the national cardiovascular data registry (NCDR). Circ Cardiovasc Qual
Outcomes. 2016;9:A138.
39. Kim K, Lee TA, Ardati AK, DiDomenico RJ, Touchette DR, Walton SM.
Comparative effectiveness of oral antiplatelet agents in patients with acute
coronary syndrome. Pharmacotherapy. 2017;37:877–887.
DOI: 10.1161/JAHA.117.007982 Journal of the American Heart Association 11
Antiplatelet Switching After Recurrent Events Fanaroff et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
  
 
Supplemental Material 
 
 
  
 by guest on A
pril 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Data S1. 
 
Variables evaluated for their association with antiplatelet intensification 
Variables collected at the time of the index event: age, sex, financial hardship of paying for 
medications, prior stroke/TIA or prior peripheral arterial disease, diabetes 
Variables related to the follow-up event: Type of event (MI with revascularization, MI without 
revascularization, revascularization without MI), stent thrombosis, time from index discharge to 
recurrent event, bleeding event between index discharge and follow-up event 
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